<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271258</url>
  </required_header>
  <id_info>
    <org_study_id>L_9524</org_study_id>
    <secondary_id>EudraCT #: 2004-004687-76</secondary_id>
    <nct_id>NCT00271258</nct_id>
  </id_info>
  <brief_title>Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents</brief_title>
  <acronym>ADOKOT</acronym>
  <official_title>STUDY OF THE TOLERANCE OF SODIUM DIVALPROATE (DEPAKOTE) IN ADOLESCENTS IN MANIC, MIXED OR HYPOMANIC EPISODES OF BIPOLAR DISORDER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      - Main objective: To evaluate the clinical and physiological tolerance of sodium divalproate
      in manic, mixed or hypomanic episodes of bipolar disorder in adolescents treated for 6
      months.

      - Secondary objective: To evaluate the efficacy of sodium divalproate in improving manic,
      mixed or hypomanic symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical examination</measure>
  </primary_outcome>
  <enrollment>200</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SODIUM DIVALPROATE</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescent boys or girls aged 13 to 18 inclusive

          -  Weighing more than 40 kg

          -  Capable of understanding the protocol

          -  Who have given their written consent, as have their parents or legal guardian unless
             the adolescent has passed his/her 18th birthday

          -  Presenting the diagnostic characteristics of manic, mixed or hypomanic episodes of
             bipolar disorder established in accordance with the DSM IV, gathered in a
             semi-structured interview (Mini International Neuropsychiatric Interview - M.I.N.I.)

          -  With a score on the YMRS scale (Young Mania Rating Scale) &gt;= 14 for the manic or mixed
             episode or &gt;= 10 for the hypomanic episode

          -  Absence in blood of valproic acid at the inclusion visit

          -  Willing to use effective contraception in the case of girls of child-bearing
             potential. In this case the investigator should satisfy him/herself as to the
             psychological capacity of the patient to understand and undertake use of this
             contraception.

          -  Whose physiological test results are normal: hepatic function, blood count, lipid
             levels, fasting blood glucose level, blood urea, blood ammonia, blood protein, serum
             creatinine levels and plasma ions

        Exclusion Criteria:

          -  General criteria:

               -  Pregnant girls, or those breast-feeding or those for whom a pregnancy test is
                  positive (blood beta HCG test)

               -  Simultaneous participation in another study or in the 2 months preceding
                  selection of the patient

          -  Psychiatric criteria:

               -  Established or known mental retardation

               -  Autistic disorders

               -  Established schizophrenia

               -  Schizoaffective disorders

          -  Somatic criteria:

               -  Medical or organic disease of the CNS (epilepsy, tumour etc.)

               -  Any known renal, cardiac or haematological disease, or disease of the immune
                  system

               -  Endocrine disorders and/or any biochemical abnormality known or existing at the
                  moment of inclusion

          -  Exclusion criteria linked to the treatment

               -  Known hypersensitivity to valproate or to sodium divalproate or to one of the
                  constituents of the drug

               -  Hepatic disease: acute hepatitis, chronic hepatitis, past personal or family
                  history of severe hepatitis particularly caused by medicinal products, hepatic
                  porphyria

               -  Treatment with lamotrigine, (Lamictal)

               -  Treatment with mefloquine, (Lariam)

               -  Any treatment based on valproate

               -  Treatment with methylphenidate (Ritalin)

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie SEBILLE, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2005</study_first_submitted>
  <study_first_submitted_qc>December 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2005</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

